From Insight to Impact: Accelerating precision medicine adoption with the 6A™ Strategic Framework

Kevin Entwistle has over 15 years of experience working in the pharmaceutical industry and supporting global leaders to develop impactful commercialization strategies for the launch of precision medicines. He has previously worked for Qiagen, Leica Biosystems and J&J. Kevin’s expertise extends across multiple indications including oncology, neurology, immunology, cardiovascular and rare diseases.

As VP of Scientific & Advisory Services at Diaceutics, Kevin utilizes his extensive experience and Diaceutics’ real-world data to provide pharmaceutical and biotech customers with a deep understanding of the current precision medicine landscape and the strategic guidance required to successfully launch therapies to market, enhancing patient outcomes and driving the adoption of precision medicines.

Dana is a Precision Medicine leader with over 15 years of experience across diagnostics, pharma, and biotech. As Principal at Diaceutics, she partners with clients to shape and execute diagnostic commercialization strategies —supporting CDx development and partnerships, patient identification, customer engagement strategies, launch planning, and life cycle management initiatives. Dana brings deep insight into evolving marketing landscapes, helping pharma and biotech teams align diagnostics with strategic goals and deliver value across oncology and rare disease.

Amy Gorman is the International Precision Medicine & Diagnostics Oncology Commercial Leader at AbbVie. She has two decades of oncology industry experience spanning diagnostics, device, and pharma in both medical affairs and commercial. Her work has focused on solid tumors, malignant hematology, and rare disease; with a passion towards shaping strategy for Precision Medicine to drive meaningful impact for patients. Prior to her time in oncology industry, Amy spent five years in the lab focused on pathology as a Cytologist.